The STAR 3 randomized clinical trial compared the metabolic control of diabetes in patients treated with a sensor‐augmented personal insulin pump and the metabolic control of patients using multiple insulin pen injections with self‐measured blood glucose. This evidence concerns the gene INS and diabetes mellitus.